Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Feasibility of circulating tumor DNA (ctDNA) to guide organ preservation in patients with node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II CCTG CO.28 trial.
Authors
Jonathan M. Loree
BCCA-Vancouver Cancer Centre, Vancouver, BC, Canada;
Jonathan M. Loree , Russell Madison , Christopher J. O'Callaghan , Carl J Brown , Dongsheng Tu , Derek J. Jonker , Max Sherry , Alexander D. Fine , Yanmei Huang , William Camara , Prapti Pokharel , Alexey Aleshin , Geoffrey R. Oxnard , Hagen Fritz Kennecke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Translational Research
Clinical Trial Registration Number
NCT03259035
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 180)
DOI
10.1200/JCO.2023.41.4_suppl.180
Abstract #
180
Poster Bd #
K2
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
CO.28: Neoadjuvant Chemotherapy, Excision and Observation (NEO) for early rectal cancer.
First Author: Hagen F. Kennecke
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prospective observational study of monitoring gene alterations in plasma cell-free DNA using droplet digital PCR system during anti-EGFR antibody treatment in patients with RAS wild-type advanced colorectal cancer.
First Author: Naoki Takahashi
Poster
2021 ASCO Annual Meeting
Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.
First Author: Giulia Martini
Poster
2016 Gastrointestinal Cancers Symposium
Perioperative chemotherapy using FOLFOX with panitumumab for locally advanced rectal cancer: Phase II trial.
First Author: Mitsuyoshi Ota